CEA in Evaluation of Adnexal Mass: Retrospective Cohort Analysis and Review of the Literature

Sagi‐Dain, Lena; Lavie, Ofer; Auslander, Ron; Sagi, Shlomi

doi:10.5301/jbm.5000158

Cited by 20 publications

(12 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…53 81 84 91 96-109 The combination of a more extended tumor marker profile, including the addition of carcinoembryonic antigen (CEA) and/or carbohydrate antigen (CA 19-9) to CA 125, is useful mainly for differentiating between metastatic tumors from the gastrointestinal tract or pancreas and primary ovarian malignancy. [110][111][112][113] Statements on tumor markers (Statements 7-12)…”

Section: Tumor Markersmentioning

confidence: 99%

ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors

Timmerman

Planchamp

Bourne

et al. 2021

Int J Gynecol Cancer

View full text Add to dashboard Cite

The European Society of Gynaecological Oncology (ESGO), the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG), the International Ovarian Tumour Analysis (IOTA) group, and the European Society for Gynaecological Endoscopy (ESGE) jointly developed clinically relevant and evidence-based statements on the pre-operative diagnosis of ovarian tumors, including imaging techniques, biomarkers, and prediction models. ESGO/ISUOG/IOTA/ESGE nominated a multidisciplinary international group, including expert practising clinicians and researchers who have demonstrated leadership and expertise in the pre-operative diagnosis of ovarian tumors and management of patients with ovarian cancer (19 experts across Europe). A patient representative was also included in the group. To ensure that the statements were evidence-based, the current literature was reviewed and critically appraised. Preliminary statements were drafted based on the review of the relevant literature. During a conference call, the whole group discussed each preliminary statement and a first round of voting was carried out. Statements were removed when a consensus among group members was not obtained. The voters had the opportunity to provide comments/suggestions with their votes. The statements were then revised accordingly. Another round of voting was carried out according to the same rules to allow the whole group to evaluate the revised version of the statements. The group achieved consensus on 18 statements. This Consensus Statement presents these ESGO/ISUOG/IOTA/ESGE statements on the pre-operative diagnosis of ovarian tumors and the assessment of carcinomatosis, together with a summary of the evidence supporting each statement.

show abstract

Section: Tumor Markersmentioning

confidence: 99%

ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors

Timmerman

Planchamp

Bourne

et al. 2021

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…Carcinoembryonic antigen (CEA) is one of the longest known tumor antigens [27], and at present is still the most widely used tumor marker in the management of colorectal cancer [28, 29]. Elevated serum levels of this assay were demonstrated in patients with ovarian adenocarcinomas, up to 87–88% in mucinous histotypes [30]. Elevation of preoperative serum CEA was also strongly correlated with advanced stage in patients with primary MOC and most likely indicated a poor prognosis [31].…”

Section: Discussionmentioning

confidence: 99%

Higher expression of calcineurin predicts poor prognosis in unique subtype of ovarian cancer

Xin

Liu

et al. 2019

J Ovarian Res

View full text Add to dashboard Cite

Background The role of calcineurin/NFAT signaling in ovarian cancer has been unknown. NFAT was significantly overexpressed in ovarian cancer tissues and that overexpression of NFAT was significantly associated with metastasis and poor prognosis on clinical tissue level. To investigate whether NFAT upstream protein, calcineurin (CN), affects the prognosis in various histological subtype of ovarian cancer (OC). Methods The association between CN and clinical features was analyzed in 50 OC patients treated from 2007 to 2012. CN expression was examined using immunohistochemistry. We observed the association of CN expression with the prognosis in these patients. Results CN expression was significantly increased in later-stage tumor tissue of serous carcinoma compared with those with early-stage. The expression of CN positively correlated with the serum cancer antigen 125 (CA125) level in ovarian clear-cell carcinoma and the serum alpha-fetoprotein (AFP) level in papillary serous cystadenocarcinoma. Particularly, higher CN expression in tumor tissues significantly correlated with reduced overall survival among patients with serous carcinoma. In addition, the serum cancer antigen 72–4 (CA72–4) level, serum carcinoembryonic antigen (CEA) levels, pathological stage, lymph node metastasis, and chemotherapeutic resistance were identified as significant prognostic factors in ovarian clear-cell carcinoma, serous carcinoma, or papillary serous cystadenocarcinoma. Conclusions CN is upregulated in ovarian cancer tissues with later-stage and that the expression of CN, CA72–4, and CEA was remarkably associated with poor prognosis in unique subtype of ovarian cancer. CN levels may be investigated for use as a prognostic biomarker for risk assessment in unique subtype of OC patients. Electronic supplementary material The online version of this article (10.1186/s13048-019-0550-0) contains supplementary material, which is available to authorized users.

show abstract

“…The glycoprotein, with a half-life of approximately 7 days, was found to be expressed in gastrointestinal and mucosal tissue during fetal development but only minimally expressed in adult tissue (15,16). Further studies showed that it was also overexpressed in adenocarcinomas of varying origin including gastric, hepatic, lung, pancreatic, ovarian and prostate (17)(18)(19)(20)(21)(22)(23)(24). In colon cancer, the specificity and sensitivity of CEA has been shown to vary with advancing tumor stage, with specificity ranging between 37% and 86% in advanced disease, providing a useful means of monitoring disease (25)(26)(27).…”

Section: Discussionmentioning

confidence: 99%

Cancer Antigen 72-4 for the Monitoring of Advanced Tumors of the Gastrointestinal Tract, Lung, Breast and Ovaries

Mariampillai

Cruz

Suh³

et al. 2017

View full text Add to dashboard Cite

show abstract

CEA in Evaluation of Adnexal Mass: Retrospective Cohort Analysis and Review of the Literature

Cited by 20 publications

References 50 publications

ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors

ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors

Higher expression of calcineurin predicts poor prognosis in unique subtype of ovarian cancer

Cancer Antigen 72-4 for the Monitoring of Advanced Tumors of the Gastrointestinal Tract, Lung, Breast and Ovaries

Contact Info

Product

Resources

About